Maravai LifeSciences Holdings, Inc. Q2 FY2026 earnings call

Overall Quarterly Performance

• The company delivered total Q2 2026 revenue of $51.4 million, a 9% year-over-year increase. Adjusted gross margin expanded 1600 basis points year-over-year to 58.9%, and adjusted EBITDA improved by $19.1 million year-over-year to $8.7 million.
• In June 2026, the company refinanced its debt, cutting total borrowings in half to approximately $147.1 million and extending debt maturities to 2032. The company ended the quarter with $70.1 million in cash, resulting in significantly strengthened liquidity and financial flexibility.

Innovation Progress

• TriLink launched a new GMP-grade Ensign portfolio, strengthening its competitive position as an integrated single-source manufacturing partner for customers.
• ModTill (Mottail) technology, launched commercially one year prior, has been adopted by more than 125 customers including leading global pharmaceutical companies, with accelerating adoption via new accounts, repeat orders, and expanded use across applications. A GMP-grade ModTill launch is planned for H2 2026, with strong customer interest particularly for cell and gene therapy applications.
• Cygnus launched a new residual protein mix-and-go kit and continues to invest in mass spec analytical services, which is seeing growing customer engagement and repeat business despite longer sales cycles.
• TriLink received a new China patent covering a full family of CleanCap capping analogs, reinforcing the company's global intellectual property portfolio.

Commercial Execution

• Q2 2026 set a record for new customer acquisition at TriLink, with 67 new customers added, and the company's e-commerce platform delivered record quarterly revenue. GMP consumables grew 55% year-over-year, driven by large CleanCap clinical orders and the company's first GMP enzyme order. There was no COVID-related GMP revenue in the quarter.
• Management provided a new framework to help investors understand growth drivers within TriLink, broken into three internal categories (external segment reporting remains unchanged): (1) mRNA (≈35% of 2026 expected revenue excluding COVID CleanCap, expected high single-digit to low double-digit long-term growth), (2) CDMO (<5% of 2026 expected revenue, project-based and variable, serving strategic cell and gene therapy customers), and (3) specialty chemistry (≈20% of 2026 expected revenue, stable recurring revenue with attractive margins).

Operational Excellence

• Restructuring actions implemented in the prior year are largely complete, and combined with debt refinancing, the company has fundamentally reset its cost structure. Existing manufacturing infrastructure (mRNA facilities and new GMP enzyme facility) is already in place to support future growth with only modest incremental fixed costs, creating meaningful operating leverage for long-term profitability.

Maravai LifeSciences reports two operating segments for Q2 2026: 1. TriLink: Generated 67% of total company revenue, contributed $7 million in adjusted EBITDA, an improvement of more than $14.2 million year-over-year. Growth was driven by high-margin GMP consumables and discovery mRNA categories, while the Specialty Chemistry category remained steady. The CDMO category declined year-over-year, which was in line with management expectations tied to customer program timing. 2. Cygnus: Generated 33% of total company revenue, delivered $11.4 million in adjusted EBITDA with a 68% adjusted EBITDA margin. The segment saw steady demand for HCP analyzer kits, with stronger-than-usual ordering in China driven by distributor timing, and marked its fifth consecutive quarter of year-over-year revenue growth. Corporate-level expenses reduced total adjusted EBITDA by $9.7 million in the quarter.

• Management maintained the 2026 full-year revenue guidance range of $205 million to $215 million, which represents 10% to 16% year-over-year growth over 2025. TriLink is expected to grow in the high teens, driven by strength in GMP and discovery mRNA consumables, while Cygnus is expected to deliver low to mid-single-digit growth. The revenue range was maintained due to the inherent program-driven variability of large GMP consumables and CDMO orders, where order timing can shift meaningfully between quarters, and management's prudent practice of not including uncertain orders in guidance until visibility is confirmed.
• Management raised full-year 2026 adjusted EBITDA guidance to $33 million to $35 million, representing a $64 million to $66 million year-over-year improvement, driven by stronger-than-expected performance at TriLink, favorable product mix shift to higher-margin segments, and completed structural cost improvements.
• Gross margin is now expected to expand by more than 1400 basis points full-year 2026, supported by prior restructuring actions, ongoing cost discipline, favorable product mix, and stronger-than-expected first half performance. All other elements of the prior guidance framework from Q1 2026 remain unchanged.

• Large program-driven orders in the CDMO and GMP consumables segments have inherent timing variability, which can cause quarterly results to deviate from expected ranges even when underlying demand remains strong.
• Forward-looking statements about future revenue, profitability, and product adoption are inherently uncertain, and actual results may differ materially from current expectations. The company undertakes no obligation to update forward-looking statements after the call.
• Commercial revenue from non-COVID mRNA customer programs is not expected to become a meaningful growth driver until 2028-2029, and the timing of this growth is controlled by Maravai's customers, not the company itself.

Q: The maintained full-year revenue guidance implies a lower sequential quarterly run rate in the second half of 2026. What drives this conservatism, and when will GMP Mottail and the newly launched GMP enzymes contribute revenue?

A: Q3 is inherently a lower revenue quarter for the business, and the 55% GMP growth in Q2 2026 was an unusually strong result that included large orders that would not typically fall in a single quarter. A few large potential orders may shift into 2027, so management maintains a prudent guidance range rather than adjusting for uncertain timing. GMP Mottail will launch in H2 2026, but no revenue from the product is expected until 2027; the first GMP enzyme order has already shipped.

Q: The e-commerce commercial strategy has delivered record new customers and revenue. How is it performing relative to expectations, and how should we expect it to ramp going forward?

A: The e-commerce platform is performing much better than management initially expected, with significant order and revenue volume flowing through the platform with minimal human interaction. It primarily serves the small-order discovery segment, and the majority of TriLink's new customer growth in Q2 2026 came through the e-commerce channel, driven by improved ordering automation, data-driven customer engagement, and predictive analytics. The platform has been a key driver of the rebound in the basic research customer segment.

Q: Can you confirm that the decision to maintain revenue guidance is due only to prudence around lumpy large order timing, not due to slowing underlying demand or customer behavior? Are you planning to continue providing the new TriLink sub-segment disclosures to investors quarterly?

A: The maintained guidance is purely due to the inherent variability of large program-driven orders, and underlying demand across all core segments (new customer acquisition, GMP consumables, e-commerce) strengthened in Q2 2026. Small and mid-size recurring orders are seeing significant growth, and the number of progressing clinical customer programs continues to grow. Management confirmed it will continue providing the TriLink sub-segment visibility to investors on an ongoing basis.

Q: Discovery mRNA growth is strong — is this due to improving biotech funding conditions, and are you on track to convert 9 early-stage customers to GMP in 2026?

A: Broader biotech funding conditions have improved, and this is supporting the strong uptick in discovery demand across basic research to late preclinical development. Management confirmed it remains on track to convert 9 customers to GMP in 2026: 2 converted in Q1, 4 converted in Q2, and the remaining 3 are expected to convert in the second half of the year.